Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Active not recruiting 29Recruiting 13Not yet recruiting 5Completed 4Withdrawn 3Unknown 3Suspended 3

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Gynecologic 1CNS 1

Conditions

Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1

Interventions

Specimen Handling 21Biopsy 15Magnetic Resonance Spectroscopy 12Cyclophosphamide 4decitabine and cedazuridine drug combination 3X-Rays 3Vincristine 3Nivolumab 3Doxorubicin 3venetoclax 2trastuzumab deruxtecan 2olaparib 2iadademstat 2Taxes 2Surgical Procedures, Operative 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Prednisone 2Ipilimumab 2Immunoglobulin G 2Disulfides 2Cetuximab 2CTLA-4 Antigen 2Azacitidine 2Actinium 2(225)Ac-DOTA-c(RGDyK) 2sargramostim 1relatlimab 1prednylidene 1neratinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Suspended × NIH × X-Rays × Clear all
NCT04539366 2026-05-13

Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial

National Cancer Institute (NCI)

Phase 1 Suspended
67 enrolled
CNSSarcoma

Neuroblastoma, Osteosarcoma

NCT04840589 2026-05-13

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

National Cancer Institute (NCI)

Phase 1 Suspended
66 enrolled
Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms

NCT06888323 2026-04-13

Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
Myeloid

Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡